Closed · RFA-CA-24-028 · CFDA 93.393;93.394;93.395;93.396 · Discretionary
Limited Competition: AIDS Malignancy Consortium (AMC; UM1 Clinical Trial Required)
Federal grant opportunity posted by National Institutes of Health, cataloged on Grants.gov.
- Varies
- Award range
- Closed
- Status
- January 10, 2025
- Close date
- -
- Expected awards
The verdict
Limited Competition: AIDS Malignancy Consortium (AMC; UM1 Clinical Trial Required) is a closed discretionary listing from National Institutes of Health that offered Varies by applicant. Future funding cycles may be published under the same CFDA number. PlainGrants indexes 12,419 other opportunities from National Institutes of Health.
- Varies
- award range
- Closed
- application status
- 93.393;93.394;93.395;93.396
- CFDA program
- 12,419
- other opportunities from National Institutes of Health
Archived opportunity record
Limited Competition: AIDS Malignancy Consorti… is closed (last close January 10, 2025). Check the agency catalog for replacement NOFOs. National Institutes of Health still indexes 12,419 other opportunities here.
According to Grants.gov (extract vintage 2026-08-10), this record reflects the officially published listing. See methodology.
Deadline tracker
Application window closed
Closed January 10, 2025
Instrument
Cooperative Agreement
Description
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to enable the provision of support for AIDS Malignancy Consortium (AMC). AMC is a major infrastructure intended to stimulate cooperative research efforts in the following areas: Design, development, and evaluation of clinical interventions for the prevention and treatment of HIV-associated malignancies; Development of more effective therapeutics and management strategies for HIV-associated malignancies; Investigation of the biology of HIV malignancies within the context of clinical trials; Management of issues of international importance in HIV associated-malignancies; and Distribution of excess tumor tissue and other relevant biologic fluids to the AIDS and Cancer Specimen Resource (ACSR) for ongoing or future investigations. The AMC must consist of the following functional units: a Coordination Center; Clinical Trial Sites; Network Laboratories; and a Statistical Center. The AMC team must have scientific disease-oriented Working Groups to study Kaposi Sarcoma, Hematologic Malignancies , Human papilloma virus-associated cancers, and Solid Tumors in people with HIV. The Network Laboratories will be responsible for routine clinical trial support activities, pathogenesis-driven correlative studies, and clinical pharmacology and pharmacokinetics studies of anticancer/antiviral interactions. All clinical trials to be conducted by the AMC must be available to subjects of all racial/ethnic groups.
Small-business / for-profit corridor · RFA-CA-24-028
Limited Competition: AIDS Malignancy Consorti… prints a for-profit / small-business applicant door (Small businesses). Treat the listing as business-facing unless the full Grants.gov announcement narrows it further. The extract does not mark applicant cost-sharing as required. Instrument: Cooperative Agreement. Funding-activity codes span Education · Health (ED;HL). 789 other National Institutes of Health listings share this eligibility-code string (6% of 12,420).
- Code 23
- Small businesses
Codes are Grants.gov eligibility category values from the extract vintage 2026-08-10. Confirm the full eligibility statement on the official listing or the Grants.gov eligibility reference.
Official Listing on Grants.gov
View full details, application forms, and submission instructions.
Agency Contact
NIH Grants Information grantsinfo@nih.gov
More from National Institutes of Health
Validation Center for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U54 Clinical Trials Not Allowed)
Logistics Center for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U24 Clinical Trials Not Allowed)
Development and Testing of a Multi-use Frameworks Playbook for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U01 Clinical Trial Not Allowed)
PRIMED-AI: Data-to-Model Academic-Industrial Partnerships (D2M-AIP) for Precision Medicine with AI: Integrating Imaging with Multimodal Data (UG3/UH3 Clinical Trial Optional)
Model-to-Clinic (M2C) for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (UG3/UH3, Clinical Trial Optional)
What to do next
Limited Competition: AIDS Malignancy Consorti… is closed; use the parent program and agency catalog for the next funding cycle.
- Browse open federal opportunities in the same category when this listing is closed. Open opportunities
- Look up CFDA 93.393;93.394;93.395;93.396 across all indexed listings before you commit to this opportunity alone. Eligibility finder
- National Institutes of Health lists 12,419 other indexed opportunities on PlainGrants. Agency catalog
Opportunity deadlines and eligibility change on Grants.gov; PlainGrants mirrors the extract and is not the submission system.
Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.
Read our methodology - how this data is sourced, computed, and verified.
| Publisher | PlainGrants |
| Sources | the SAM.gov Assistance Listings and Grants.gov |